Pharmaceuticals Africa

Africa Sickle Cell Disease Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Africa Sickle Cell Disease Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Africa · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $42.8 Mn Placeholder estimate
Estimate 2025 $51.1 Mn 1.3% of the global market
Projected 2034 $250.1 Mn 389.5% Adds $199.0 Mn over 9 forecast years
CAGR 2025–2034 19.3% Faster than 83% of 183 Pharmaceuticals markets here
Key players 5
  • Africa is 1.31% of the global market.
  • Among regions, the largest is North America at $2.17 Bn.
  • Fastest growing: APAC at 19.3% a year.
  • Africa ranks 6th of 6 by size among regions.

Market size projection

Africa

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$199.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Sickle Cell Disease Therapeutics Market market size by year, Africa
YearMarket sizeChange that yearSince 2025
2024 (estimate) $42.8 Mn — —
2025 (base) $51.1 Mn +$8.3 Mn —
2026 (forecast) $61.0 Mn +$9.9 Mn +19.3%
2027 (forecast) $72.7 Mn +$11.8 Mn +42.3%
2028 (forecast) $86.8 Mn +$14.0 Mn +69.8%
2029 (forecast) $103.5 Mn +$16.7 Mn +102.6%
2030 (forecast) $123.5 Mn +$20.0 Mn +141.7%
2031 (forecast) $147.3 Mn +$23.8 Mn +188.3%
2032 (forecast) $175.7 Mn +$28.4 Mn +243.9%
2033 (forecast) $209.7 Mn +$33.9 Mn +310.3%
2034 (forecast) $250.1 Mn +$40.5 Mn +389.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Africa Sickle Cell Disease Therapeutics Market Analysis at a glance
Market size, 2025$51.1 Mn placeholder estimate
Forecast, 2034$250.1 Mn placeholder estimate
Growth (CAGR), 2025–203419.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledSickle Cell Disease Treatment
SegmentsTreatment, age and end user (see all)
Key playersVertex Pharmaceuticals, bluebird bio, Pfizer Inc., Novartis AG, Novo Nordisk A/S (see all)
Regulator in AfricaAMASource: African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
Active clinical trials33 in AfricaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Africa Sickle Cell Disease Therapeutics Market Analysis Executive Summary

Sickle cell disease therapeutics include gene therapies, gene editing and medicines that reduce pain crises and organ damage.

Key segments of the sickle Cell Disease Therapeutics market include treatment (Gene Therapy, Gene Editing and Hydroxyurea) and age (Pediatric and Adult).

Bar chart: Africa Sickle Cell Disease Therapeutics market size, 2024–2034, placeholder estimates. $42.8 Mn in 2024, $51.1 Mn in 2025 and $250.1 Mn in 2034, 19.3% CAGR.
Africa Sickle Cell Disease Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Africa Sickle Cell Disease Therapeutics Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the sickle Cell Disease Therapeutics market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the sickle Cell Disease Therapeutics market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the sickle Cell Disease Therapeutics market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Sickle Cell Disease Therapeutics Market in Africa

The sickle Cell Disease Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Sickle Cell Disease Therapeutics Market in Africa

Sickle Cell Disease Therapeutics in Africa: rules, payment and research

The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together.⁠[1] In some of the countries we cover here, medicines are approved by EDA (Egypt)⁠[2], PPB (Kenya)⁠[3], SAHPRA (South Africa)⁠[4] and NAFDAC (Nigeria)⁠[5]. How care is paid for in some of these countries: universal health insurance (Egypt)⁠[6], the SHA (Kenya)⁠[7], planned National Health Insurance (South Africa)⁠[8] and out of pocket and the NHIA (Nigeria)⁠[9]. ClinicalTrials.gov lists 33 studies on Sickle Cell Disease Therapeutics that are recruiting, active or about to start in Africa.⁠[10]

[1] African Union, African Medicines Agency treaty. Checked 14 Nov 2026.

[2] Egyptian Drug Authority. Checked 14 Nov 2026.

[3] Pharmacy and Poisons Board. Checked 14 Nov 2026.

[4] South African Health Products Regulatory Authority. Checked 14 Nov 2026.

[5] NAFDAC. Checked 19 Nov 2026.

[6] Universal Health Insurance Authority. Checked 14 Nov 2026.

[7] Social Health Authority. Checked 14 Nov 2026.

[8] National Department of Health. Checked 14 Nov 2026.

[9] National Health Insurance Authority (NHIA). Checked 19 Nov 2026.

[10] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for sickle Cell Disease Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Africa.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Sickle Cell Disease Therapeutics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Sickle Cell Disease Therapeutics in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Sickle Cell Disease Therapeutics market in Africa?
Placeholder estimate: about $51.1 Mn in 2025, rising to about $250.1 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Sickle Cell Disease Therapeutics market in Africa growing?
Placeholder estimate: about 19.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Sickle Cell Disease Therapeutics market report cover?
The report splits the market by treatment (Gene Therapy, Gene Editing, Hydroxyurea, Disease-Modifying Drugs), age (Pediatric, Adult) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Sickle Cell Disease Therapeutics market?
Key players include Vertex Pharmaceuticals, bluebird bio, Pfizer Inc., Novartis AG and Novo Nordisk A/S.
What is driving the Sickle Cell Disease Therapeutics market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the sickle Cell Disease Therapeutics market.
Who regulates Sickle Cell Disease Therapeutics in Africa?
The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together. Source: African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
How many clinical trials on Sickle Cell Disease Therapeutics are running in Africa?
33 studies are recruiting, active or about to start in Africa, counted across the 17 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
How much research is published on Sickle Cell Disease Therapeutics?
PubMed lists 3,466 papers on Sickle Cell Disease Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Africa

See all

Related on rare diseases and anemia

See the topic